IDEX · IDEX BIOMETRICS ASA
Market Cap
441.37M NOK
Shares
74.81M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Investor day
Close5.3000 NOK
Open5.1400 NOK
Day5.1400–5.4600 NOK
52W close2.7000–12.3000 NOK
Avg vol 30d205K
Last earningsFeb 25, 2027
DataJul 2025–Oct 2026
Raw chart and full-history price indicators begin at the captured split on Jul 4, 2025; bars on opposite sides are not compared.
Technicals
trend & momentum for long-term holders illustrative — not investment advicePrice context
position in its 52-week range
Range low 2.7000 NOK
Now 5.3000 NOK · 27%
Range high 12.3000 NOK
vs 200-day avg -30%
vs 50-day avg -24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Performance
Raw-price comparisons begin at the captured split on Jul 4, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XOSL:IDEX | -9.9% | -13.1% | -50.0% | -3.3% | -15.9% |
Exchange listing
- Market
- XOSL
- Ticker
- IDEX
- ISIN
- NO0013536078
- Security
- —
- Trading currency
- NOK
Company
- Investor relations
- https://www.idexbiometrics.com/investors/
Other listings of this company
No other verified listings are available.
Latest trade
15-minute delayed Session complete5.3000 NOK
200 shares at 2026-10-05 12:55:04 UTC (14:55:04 local)
- Session
- 2026-10-05
- Open
- 5.1400
- High
- 5.4600
- Low
- 5.1400
- Volume
- 11,674
Recent dividends
No verified dividend payments are available for this listing yet.
Upcoming investor events
| Date | Event | Type |
|---|---|---|
| 2026-11-12 00:00 UTC | Quarterly Report 2026-Q3 | Results publication |
| 2027-02-25 00:00 UTC | Quarterly Report 2026-Q4 | Results publication |
Earnings calls
-
Earnings call · Q4 2026 2027-02-25 ScheduledQuarterly Report 2026-Q4
-
Earnings call · Q3 2026 2026-11-12 ScheduledQuarterly Report 2026-Q3
-
Earnings call · Q2 2026 2026-08-20Half-yearly Report 2026
-
Earnings call · Q1 2026 2026-05-29Quarterly Report 2026-Q1
-
Earnings call · Q4 2025 2026-03-03Quarterly Report 2025-Q4